| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US7800788 | GILEAD SCIENCES INC | Upright image processing apparatus with pivotable image reading portion |
Feb, 2022
(2 years ago) | |
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
Genvoya is owned by Gilead Sciences Inc.
Genvoya contains Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate.
Genvoya has a total of 30 drug patents out of which 10 drug patents have expired.
Expired drug patents of Genvoya are:
- US5814639*PED
- US5914331*PED
- US6642245
- US6642245*PED
- US6703396*PED
- US7800788
- US7803788
- US5814639
- US5914331
- US6703396
Genvoya was authorised for market use on 05 November, 2015.
Genvoya is available in tablet;oral dosage forms.
Genvoya can be used as treatment of hiv infection, treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
Drug patent challenges can be filed against Genvoya from 06 November, 2019.
The generics of Genvoya are possible to be released after 06 April, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
GENVOYA family patents
